Cantor Fitzgerald Comments on ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($1.12) for the year. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.63) per share.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

Separately, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Eledon Pharmaceuticals in a research note on Wednesday, November 20th.

Eledon Pharmaceuticals Trading Up 2.9 %

Shares of NASDAQ:ELDN opened at $4.21 on Wednesday. Eledon Pharmaceuticals has a 52 week low of $1.52 and a 52 week high of $5.54. The company has a market cap of $251.50 million, a PE ratio of -2.09 and a beta of 0.79. The company’s 50 day moving average is $4.27 and its two-hundred day moving average is $3.44.

Hedge Funds Weigh In On Eledon Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Clarity Capital Partners LLC acquired a new stake in Eledon Pharmaceuticals during the 3rd quarter worth approximately $29,000. Kera Capital Partners Inc. acquired a new stake in shares of Eledon Pharmaceuticals during the fourth quarter worth $106,000. Dimensional Fund Advisors LP acquired a new stake in shares of Eledon Pharmaceuticals during the second quarter worth $80,000. Renaissance Technologies LLC grew its position in Eledon Pharmaceuticals by 57.1% in the 2nd quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock valued at $361,000 after buying an additional 49,704 shares during the last quarter. Finally, Inspire Investing LLC acquired a new position in Eledon Pharmaceuticals in the 4th quarter valued at $802,000. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).